Leerink Partnrs Has Positive Estimate for EW FY2026 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Investment analysts at Leerink Partnrs lifted their FY2026 earnings per share estimates for Edwards Lifesciences in a research report issued to clients and investors on Monday, November 25th. Leerink Partnrs analyst M. Kratky now forecasts that the medical research company will post earnings of $2.90 per share for the year, up from their previous forecast of $2.87. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.57 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ FY2028 earnings at $3.75 EPS.

EW has been the topic of a number of other reports. Canaccord Genuity Group decreased their price objective on Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating on the stock in a research note on Friday, October 25th. Barclays decreased their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. UBS Group cut their price objective on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research report on Tuesday, September 10th. Morgan Stanley reaffirmed an “equal weight” rating and set a $70.00 target price on shares of Edwards Lifesciences in a report on Friday, October 11th. Finally, Truist Financial lowered their target price on shares of Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating on the stock in a research note on Friday, October 25th. Seventeen research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of “Hold” and a consensus price target of $75.90.

Edwards Lifesciences Trading Up 0.7 %

Shares of EW stock opened at $72.06 on Tuesday. The stock has a market capitalization of $42.50 billion, a price-to-earnings ratio of 10.40, a PEG ratio of 4.01 and a beta of 1.12. The company’s fifty day simple moving average is $67.92 and its two-hundred day simple moving average is $75.35. Edwards Lifesciences has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.59 EPS.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. First Community Trust NA bought a new position in Edwards Lifesciences in the 2nd quarter worth $29,000. Webster Bank N. A. bought a new position in Edwards Lifesciences in the second quarter worth about $39,000. FSA Wealth Management LLC purchased a new stake in Edwards Lifesciences in the third quarter worth about $30,000. Versant Capital Management Inc boosted its position in Edwards Lifesciences by 206.3% during the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 326 shares in the last quarter. Finally, Prospera Private Wealth LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $32,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,262,521.36. This represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,000 shares of company stock valued at $2,657,000 over the last three months. Insiders own 1.27% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.